Researchers from the University of Oxford and PsiOxus Therapeutics have successfully adapted an oncolytic adenovirus that specifically kills cancer cells, to synthesize a peptide linker that approximates cytotoxic T-cells to cancer-associated fibroblasts in order to eliminate these supportive accomplices. Cancer cells (black) and nearby fibroblasts (red) being killed (green flashes) by Enadenotucirev equipped with a bispecific T-cell engager. The...